[1] |
刘苗, 王英南, 张韶辰, 等. 影响胃癌根治术后早期复发的危险因素分析[J]. 临床肿瘤学杂志, 2020, 25(10):905-910.
|
[2] |
刘苗, 王英南, 赵群, 等. 不同Lauren分型胃癌的临床病理特征及影响胃癌根治术后复发的危险因素分析[J]. 中国肿瘤, 2019, 28(12):941-950.
|
[3] |
MA L, YANG R, GU J, et al. The expression of AGGF1,FOXC2,and E-cadherin in esophageal carcinoma and their clinical significance[J]. Medicine(Baltimore), 2020, 99(37):e22173.
|
[4] |
SYMMANS W F, WEI C, GOULD R, et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype[J]. J Clin Oncol, 2017, 35(10):1049-1060.
DOI
URL
|
[5] |
POKHAREL K, GILBAR P J, MANSFIELD S K, et al. Elevated beta human chorionic gonadotropin in a non-pregnant female diagnosed with anal squamous cell carcinoma[J]. J Oncol Pharm Pract, 2020, 26(5):1266-1269.
DOI
URL
|
[6] |
ZHAO W X, LIU Z F, LI X L, et al. Correlations of serum homocysteine,VEGF and gastrin 17 with gastric cancer and precancerous lesions[J]. Eur Rev Med Pharmacol Sci, 2019, 23(10):4192-4198.
|
[7] |
ZHOU N, GUO X, YANG M, et al. 68Ga-ZHER2 PET/CT reveals HER2-positive metastatic gastric cancer with better image quality than 18F-FDG[J]. Clin Nuclear Med, 2020, 45(2):e101-e102.
DOI
URL
|
[8] |
ULASE D, HECKL S, BEHRENS H M, et al. Prognostic significance of tumour budding assessed in gastric carcinoma according to the criteria of the International Tumour Budding Consensus Conference[J]. Histopathology, 2020, 76(3):433-446.
DOI
URL
|
[9] |
BAROK M, LE JONCOUR V, MARTINS A, et al. ARX788,a novel anti-HER2 antibody-drug conjugate,shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer[J]. Cancer Lett, 2020, 473:156-163.
DOI
URL
|
[10] |
张自森, 巴楠, 张剑, 等. 胃癌FOLFOX4方案化疗患者预后与血清可溶性E-钙黏蛋白表达的关系[J]. 中华实验外科杂志, 2016, 33(12):2773-2775.
|
[11] |
张毅, 张君薇. 血清E-Cad、PGⅠ、CEA和CA19-9单独和联合检测对胃癌诊断的临床价值[J]. 实用癌症杂志, 2018, 33(3):370-372.
|
[12] |
陈玲, 林晶, 王晓杰, 等. 人类表皮生长因子受体2在胃癌根治术后复发患者中的表达及其意义[J]. 肿瘤研究与临床, 2020, 32(3):178-181.
|
[13] |
TORABIZADEH Z, NOSRATI A, SAJADI SARAVI S N, et al. Evaluation of E-cadherin expression in gastric cancer and its correlation with clinicopathologic parameters[J]. Int J Hematol Oncol Stem Cell Res, 2017, 11(2):158-164.
|
[14] |
LIN Z, BIAN H, CHEN C, et al. Application of serum pepsinogen and carbohydrate antigen 72-4(CA72-4) combined with gastrin-17(G-17) detection in the screening,diagnosis,and evaluation of early gastric cancer[J]. J Gastrointest Oncol, 2021, 12(3):1042-1048.
DOI
URL
|
[15] |
WANG Y, ZHU Z, LIU Z, et al. Diagnostic value of serum pepsinogen Ⅰ,pepsinogen Ⅱ,and gastrin-17 levels for population-based screening for early-stage gastric cancer[J]. J Int Med Res, 2020, 48(3):300060520914826.
|
[16] |
董曲文, 陈晓, 丁纪元. 早期胃癌患者内镜黏膜下剥离术前后血清胃泌素-17、糖类抗原-125及胃蛋白酶原水平的变化和意义[J]. 中国内镜杂志, 2020, 26(2):37-42.
|
[17] |
PALLE J, ROCHAND A, PERNOT S, et al. Human epidermal growth factor receptor 2(HER2) in advanced gastric cancer:current knowledge and future perspectives[J]. Drugs, 2020, 80(4):401-415.
DOI
URL
|
[18] |
KANAYAMA K, IMAI H, USUGI E, et al. Association of HER2 gene amplification and tumor progression in early gastric cancer[J]. Virchows Arch, 2018, 473(5):559-565.
DOI
URL
|
[19] |
KIM S, KIM Y J, CHUNG W C. HER-2 positivity is a high risk of recurrence of stage Ⅰ gastric cancer[J]. Korean J Intern Med, 2021, 36(6):1327-1337.
DOI
URL
|